HUP0300736A3 - Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses - Google Patents

Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses

Info

Publication number
HUP0300736A3
HUP0300736A3 HU0300736A HUP0300736A HUP0300736A3 HU P0300736 A3 HUP0300736 A3 HU P0300736A3 HU 0300736 A HU0300736 A HU 0300736A HU P0300736 A HUP0300736 A HU P0300736A HU P0300736 A3 HUP0300736 A3 HU P0300736A3
Authority
HU
Hungary
Prior art keywords
necroses
tumours
plaques
mri
imaging
Prior art date
Application number
HU0300736A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of HUP0300736A2 publication Critical patent/HUP0300736A2/hu
Publication of HUP0300736A3 publication Critical patent/HUP0300736A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HU0300736A 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses HUP0300736A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
PCT/EP2001/008498 WO2002013874A2 (de) 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen

Publications (2)

Publication Number Publication Date
HUP0300736A2 HUP0300736A2 (hu) 2003-09-29
HUP0300736A3 true HUP0300736A3 (en) 2010-01-28

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300736A HUP0300736A3 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses

Country Status (26)

Country Link
EP (1) EP1307236A2 (de)
JP (1) JP2004506025A (de)
KR (1) KR20030022387A (de)
CN (1) CN1469757A (de)
AR (1) AR034139A1 (de)
AU (2) AU2001277549B2 (de)
BG (1) BG107542A (de)
BR (1) BR0113188A (de)
CA (1) CA2419223A1 (de)
CZ (1) CZ2003392A3 (de)
DE (1) DE10066210B4 (de)
EE (1) EE200300061A (de)
HR (1) HRP20030173A2 (de)
HU (1) HUP0300736A3 (de)
IL (1) IL154385A0 (de)
MX (1) MXPA03001287A (de)
NO (1) NO20030604L (de)
NZ (1) NZ523932A (de)
PL (1) PL365596A1 (de)
RU (1) RU2290206C2 (de)
SK (1) SK1572003A3 (de)
TW (1) TWI296931B (de)
UA (1) UA82642C2 (de)
WO (1) WO2002013874A2 (de)
YU (1) YU10603A (de)
ZA (1) ZA200301949B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) * 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (de) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Neue gadoliniumchelat-verbindung zur verwendung in der magnetresonanzbildgebung
JP7037069B2 (ja) * 2016-09-14 2022-03-16 ダイキン工業株式会社 分枝含フッ素化合物
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
KR102934987B1 (ko) 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009856A1 (en) * 1993-10-01 1995-04-13 The Regents Of The University Of California Boronated metalloporphyrins and therapeutic methods
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
NO20030604L (no) 2003-04-11
JP2004506025A (ja) 2004-02-26
IL154385A0 (en) 2003-09-17
RU2290206C2 (ru) 2006-12-27
WO2002013874A8 (de) 2002-06-13
AU7754901A (en) 2002-02-25
EE200300061A (et) 2004-12-15
MXPA03001287A (es) 2003-10-06
NO20030604D0 (no) 2003-02-07
SK1572003A3 (en) 2003-10-07
AR034139A1 (es) 2004-02-04
NZ523932A (en) 2007-07-27
KR20030022387A (ko) 2003-03-15
HRP20030173A2 (en) 2005-04-30
DE10066210B4 (de) 2008-02-28
CN1469757A (zh) 2004-01-21
BR0113188A (pt) 2003-06-24
PL365596A1 (en) 2005-01-10
WO2002013874A2 (de) 2002-02-21
BG107542A (bg) 2003-09-30
EP1307236A2 (de) 2003-05-07
HUP0300736A2 (hu) 2003-09-29
TWI296931B (en) 2008-05-21
CZ2003392A3 (cs) 2003-09-17
CA2419223A1 (en) 2003-02-11
YU10603A (sh) 2006-05-25
ZA200301949B (en) 2004-12-14
UA82642C2 (uk) 2008-05-12
AU2001277549B2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
AU2002367262A8 (en) Personal user agent
HUP0300736A3 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses
EP1435988A4 (de) Verbesserte verwendung einer antitumoralen verbindung in der krebstherapie
EP1390689A4 (de) Verminderung kohärenter artefakte in einem interferometer
EP1482985A4 (de) Technetium-dipyridin-komplexe und anwendungsverfahren dafür
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU2001261544A1 (en) Metal surface treatment agent
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
SI1545710T1 (sl) Uporaba N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamida v zdravljenju raka
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes
AU2003233431A8 (en) Protamine-adenoviral vector complexes and methods of use
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
AU6022701A (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
HUP0100318A3 (en) Salicyli denaminoalcohol derivatives, their chiral copper complexes, their preparations and use of the latter
IL174972A0 (en) Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents
IL160310A0 (en) The use of anthroquinones in the treatment of kidney disease

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees